SEARCH

SEARCH BY CITATION

References

  • 1
    Tanaka M & Miyajima A (2003) Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149, 3952.
  • 2
    Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G & Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374, 120.
  • 3
    Yu H, Pardoll D & Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798809.
  • 4
    Abel J & Haarmann-Stemmann T (2010) An introduction to the molecular basics of aryl hydrocarbon receptor biology. Biol Chem 391, 12351248.
  • 5
    Bock KW & Kohle C (2006) Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem Pharmacol 72, 393404.
  • 6
    Fernandez-Salguero PM, Ward JM, Sundberg JP & Gonzalez FJ (1997) Lesions of aryl-hydrocarbon receptor-deficient mice. Vet Pathol 34, 605614.
  • 7
    Schmidt JV, Su GH, Reddy JK, Simon MC & Bradfield CA (1996) Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 93, 67316736.
  • 8
    Tauchi M, Hida A, Negishi T, Katsuoka F, Noda S, Mimura J, Hosoya T, Yanaka A, Aburatani H, Fujii-Kuriyama Y et al. (2005) Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. Mol Cell Biol 25, 93609368.
  • 9
    Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A & Poellinger L (2002) A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci USA 99, 99909995.
  • 10
    Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197203.
  • 11
    Wolff S, Harper PA, Wong JM, Mostert V, Wang Y & Abel J (2001) Cell-specific regulation of human aryl hydrocarbon receptor expression by transforming growth factor-beta(1). Mol Pharmacol 59, 716724.
  • 12
    Stonans I, Stonane E, Russwurm S, Deigner HP, Bohm KJ, Wiederhold M, Jager L & Reinhart K (1999) HepG2 human hepatoma cells express multiple cytokine genes. Cytokine 11, 151156.
  • 13
    Schust J, Sperl B, Hollis A, Mayer TU & Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13, 12351242.
  • 14
    Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL et al. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24, 55525560.
  • 15
    Skov S, Nielsen M, Bregenholt S, Odum N & Claesson MH (1998) Activation of Stat-3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human Jurkat T cells. Blood 91, 35663573.
  • 16
    Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S & Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 1171, 5976.
  • 17
    Villard PH, Caverni S, Baanannou A, Khalil A, Martin PG, Penel C, Pineau T, Seree E & Barra Y (2007) PPARalpha transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects. Biochem Biophys Res Commun 364, 896901.
  • 18
    Braeuning A, Kohle C, Buchmann A & Schwarz M (2011) Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci 122, 1625.
  • 19
    Chesire DR, Dunn TA, Ewing CM, Luo J & Isaacs WB (2004) Identification of aryl hydrocarbon receptor as a putative Wnt/β-catenin pathway target gene in prostate cancer cells. Cancer Res 64, 25232533.
  • 20
    FitzGerald CT, Nebert DW & Puga A (1998) Regulation of mouse Ah receptor (Ahr) gene basal expression by members of the Sp family of transcription factors. DNA Cell Biol 17, 811822.
  • 21
    Puga A, Maier A & Medvedovic M (2000) The transcriptional signature of dioxin in human hepatoma HepG2 cells. Biochem Pharmacol 60, 11291142.
  • 22
    Mohammadi-Bardbori A, Bengtsson J, Rannug U, Rannug A & Wincent E (2012) Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem Res Toxicol 25, 18781884.
  • 23
    Fukuda Y & Sassa S (1994) Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 47, 11871195.
  • 24
    Guillen MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R & Gomez-Lechon MJ (1998) Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Ther 285, 127134.
  • 25
    Muntane-Relat J, Ourlin JC, Domergue J & Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22, 11431153.
  • 26
    Jover R, Bort R, Gomez-Lechon M & Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16, 17991801.
  • 27
    Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 29, 207212.
  • 28
    Nakamura K, Nonaka H, Saito H, Tanaka M & Miyajima A (2004) Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39, 635644.
  • 29
    Kinoshita T & Miyajima A (2002) Cytokine regulation of liver development. Biochim Biophys Acta 1592, 303312.
  • 30
    Abbott BD, Birnbaum LS & Perdew GH (1995) Developmental expression of two members of a new class of transcription factors: I. Expression of aryl hydrocarbon receptor in the C57BL/6N mouse embryo. Dev Dyn 204, 133143.
  • 31
    Jain S, Maltepe E, Lu MM, Simon C & Bradfield CA (1998) Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev 73, 117123.
  • 32
    Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM & Gonzalez FJ (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268, 722726.
  • 33
    Lahvis GP, Lindell SL, Thomas RS, McCuskey RS, Murphy C, Glover E, Bentz M, Southard J & Bradfield CA (2000) Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci USA 97, 1044210447.
  • 34
    Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ Jr, Roberts AB & Gonzalez FJ (1998) The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol Pharmacol 54, 313321.
  • 35
    Abdelrahim M, Smith R & Safe S (2003) Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol Pharmacol 63, 13731381.
  • 36
    Ma Q & Whitlock JP Jr (1996) The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol Cell Biol 16, 21442150.
  • 37
    Wu R, Zhang L, Hoagland MS & Swanson HI (2007) Lack of the aryl hydrocarbon receptor leads to impaired activation of AKT/protein kinase B and enhanced sensitivity to apoptosis induced via the intrinsic pathway. J Pharmacol Exp Ther 320, 448457.
  • 38
    Liu Z, Wu X, Zhang F, Han L, Bao G, He X & Xu Z (2013) AhR expression is increased in hepatocellular carcinoma. J Mol Histol 44, 455461.
  • 39
    Kung T, Murphy KA & White LA (2009) The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism. Biochem Pharmacol 77, 536546.
  • 40
    He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL & Karin M (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286297.
  • 41
    He G & Karin M (2011) NF-kappaB and STAT3 – key players in liver inflammation and cancer. Cell Res 21, 159168.
  • 42
    Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R & Royuela M (2005) IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47, 8289.
  • 43
    Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM & Reed MJ (1995) Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrin Metab 80, 30523058.
  • 44
    Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A & Frank DA (2005) Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65, 50545062.
  • 45
    Vogel CF, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y & Matsumura F (2011) Interaction of aryl hydrocarbon receptor and NF-kappaB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch Biochem Biophys 512, 7886.
  • 46
    Brooks J & Eltom SE (2011) Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. Curr Cancer Drug Targets 11, 654669.
  • 47
    Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH et al. (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179, 43134317.
  • 48
    Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS & Dong C (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282, 93589363.
  • 49
    Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC & Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106109.
  • 50
    Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M & Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 6571.
  • 51
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL & Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235238.
  • 52
    Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM & Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179189.
  • 53
    Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y & Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 105, 97219726.
  • 54
    Tigges J, Weighardt H, Wolff S, Gotz C, Forster I, Kohne Z, Huebenthal U, Merk HF, Abel J, Haarmann-Stemmann T et al. (2013) Aryl hydrocarbon receptor repressor (AhRR) function revisited: repression of CYP1 activity in human skin fibroblasts is not related to AhRR expression. J Invest Dermatol 133, 8796.